Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2004

View Archived Issues

Sanofi-Synthelabo achieves highly favorable R&D results during past year

Merck KgaA highlights 2003 developments

Toll-like receptor 4 involved in outward arterial remodeling in vivo

Inhibition of viral replication achieved with TNX-355 in HIV-infected patients

Gabapentin found effective against tamoxifen-related hot flashes in breast cancer

Clinical benefits associated with sitaxsentan in PAH

Promising preclinical results with Vertex's Aurora kinase inhibitor VX-680

FDA agrees to dose range finding study for ISA-247

Bionomics and WEHI form ion channel drug discovery collaboration

Protez acquires assets of Influx

NanoBio anticipates initiation of phase II cold sore trials

Callisto acquires rights to novel cancer technology platform

OSI expands ongoing phase I study of OSI-461

Milestone achievement in Arena and Merck GPCR collaboration

Expansion in GenVec SARS subcontract

New phase II/III trial for Dynavax ragweed allergy product

Diatos secures financing to advance development of DTS-201

Hollis-Eden acquires Congressional Pharmaceutical

Humaspect European marketing authorization expires

Two series of kinase/phosphatase inhibitors and their use in cancer and cardiovascular disorders

Novel PPARdelta agonists identified by Sumitomo researchers

Pharmacia claims new protein kinase inhibitors for cancer and other disorders

New antibacterial agents targeting LpxC designed at Vicuron

Novel sigma receptor ligands with hypocholesterolemic activity claimed by LEK

Collaborative research results in novel purine-based antiviral agents

Novel DPP-IV inhibitors covered by Merck patent

New antidiabetic agents in early development at Aventis

Increased half-lives of engineered human IgG antibodies reported

Sosei and Arachnova in licensing agreement in stress urinary incontinence

Abraxane enters new studies in NSCLC and metastatic melanoma

SGN-30 receives orphan drug designation for T-cell lymphomas

Suppression of MS symptoms in vivo with Neurodur

Avastin approved for first-line metastatic colorectal cancer